Bcal Diagnostics Share Price and Company Fundamentals

0.004 (4.938%)
52 week
0.059 - 0.225

Last traded: Last Friday at 5:14 AM

BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield




Market cap


Enterprise value


Company profile

Primary activitiesBCAL Diagnostics Limited is a biotechnology company developing a blood based diagnostic test for breast cancer.
Industry / SectorDiagnostics & Research / Healthcare
Mailing address50 Clarence Street Suite 506 Level 5 Sydney NSW 2000 Australia
Phone / Fax61 2 9078 7671 /


More: Bcal Diagnostics Dividend history, yield and payout ratio

Dividend yield


Dividend amount


Payout ratio

Bcal Diagnostics paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is . The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.

BDX's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of Aug 2022, following are the company executives and directors listed on Bcal Diagnostics.

NameTitleAgeTotal Pay
Ms. Jayne Andrea ShawCo-Founder & Exec. Chairman90k
Hon. Ronald Anthony Phillips A.O.Co-Founder & Non-Exec. Director25k
Dr. Amani Batarseh Ph.D.Chief Scientist Officer259k
Dr. John G. Hurrell B.Sc, Fulbright Fel, M.Sc(Qual), Ph.D.Chief Exec. Officer
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), C.A., CA, MAICDCFO & Company Sec.
Dr. Jane Ryan Bsc (Hons), M.A.I.C.D., Ph.D.Chief Operating Officer61
Sean KennedyDirector of Corp. Fin.
Ms. Rebecca ShawMarketing Mang.

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Bcal Diagnostics is and its enterprise value is .

Companies similar to Bcal Diagnostics (BDX)

Bcal Diagnostics (ASX:BDX) Frequently Asked Questions

1. What is Bcal Diagnostics's Stock Symbol?

Bcal Diagnostics trades on ASX under the ticker symbol "BDX".

2. What is Bcal Diagnostics's stock price today?

One share of BDX stock can currently be purchased for approximately $0.085.

3. How can I contact Bcal Diagnostics?

Bcal Diagnostics's mailing address is 50 Clarence Street Suite 506 Level 5 Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 9078 7671.

4. What is Bcal Diagnostics's official website?

The official website of Bcal Diagnostics is https://www.bcaldiagnostics.com.

5. Which share registry manages Bcal Diagnostics's stock?

Bcal Diagnostics's stock is managed by AUTOMIC REGISTRY SERVICES.